PROCEPT BioRobotics Corporation
PRCT
NASDAQ·Healthcare·Medical - Devices·Mkt cap $1.3B
$22.76
▲ +6.50%
P/E
-24.74
Mkt Cap
$1.3B
52-Wk Range
$16.67–$41.51
52-Week Range
$16.67 - $41.51
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary image-guided robotic platform with aquablation technology
- Focused specialization in urology with deep clinical expertise
- Growing installed base and expanding surgeon adoption network
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Rising BPH prevalence in aging male population
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Weak
-19.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.47 vs -$0.46 consensus (-1.8% surprise). Revenue of $94.5M vs $92.8M expected (+1.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.8%
Revenue trend · last 8Q
—
+57%
+55%
+48%
+43%
+12%
+20%
+19%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$58.4M
$68.2M
$69.2M
$79.2M
$83.3M
$76.4M
$83.1M
$94.5M
Margins · last 8Q
Gross
66.0%
Operating
-29.0%
Profit
-28.4%
Wall Street consensus
6 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 5, 2026
vs Industry
How PRCT stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related